OncoMatch/Clinical Trials/NCT06387342
Namodenoson Treatment of Advanced Pancreatic Cancer
Is NCT06387342 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Namodenoson 25mg for pancreatic adenocarcinoma.
Treatment: Namodenoson 25mg — This is an open-label trial in patients with advanced pancreatic cancer. The trial will evaluate the safety, clinical activity, and pharmacokinetics of the study drug, namodenoson, in this group of patients.
Check if I qualifyExtracted eligibility criteria
Cancer type
Pancreatic Cancer
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: systemic treatment
Pancreatic adenocarcinoma has progressed on at least 1 prior systemic treatment regimen, or the patient refuses standard treatment.
Cannot have received: systemic cancer therapy
Receipt of systemic cancer therapy within 14 days prior to the Baseline Visit or concurrently during the trial.
Cannot have received: major surgery or radiation therapy
Major surgery or radiation therapy within 14 days prior to the Baseline Visit.
Cannot have received: investigational agent
Use of any investigational agent within the shorter of 4 weeks or 5 half-lives prior to the Baseline Visit.
Lab requirements
Blood counts
Absolute neutrophil count (ANC) ≥1.5 × 10^9/L; Platelet count ≥50 × 10^9/L
Kidney function
Creatinine clearance ≥50 mL/min (estimated glomerular filtration rate by the Cockcroft-Gault) or serum creatinine ≤2.0 mg/dL
Liver function
AST and ALT ≤10X the upper limit of normal; total bilirubin ≤10 mg/dL; serum albumin ≥2.0 g/dL
The following laboratory values must be documented prior to the first dose of study drug: Absolute neutrophil count (ANC) ≥1.5 × 10^9/L; Platelet count ≥50 × 10^9/L; Creatinine clearance ≥50 mL/min (estimated glomerular filtration rate by the Cockcroft-Gault) or serum creatinine ≤2.0 mg/dL; Aspartate aminotransferase (AST) and Alanine transaminase (ALT) ≤10X the upper limit of normal; Total bilirubin ≤10 mg/dL; Serum albumin ≥2.0 g/dL.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify